Augmented glucose dependency of autoreactive B cells provides a treatment target forlupus
J. J. Wilson, J. Wei, A. R. Daamen, J. D. Sears, E. Bechtel, C. L. Mayberry, G. A. Stafford, L. Bechtold, A. C. Grammer, P. E. Lipsky, D. C. Roopenian, C.-H. Chang
This study identifies glycolysis-dependent autoreactive B cells as key mediators of lupus and shows that targeting them with 2DG or BCMA-specific CAR T-cells improves disease outcomes.
bioRxiv · Feb 1, 2022Immunology